1. Maher, D. & Mikulencak, M. (1999). What is DOTS? A guide to understanding the WHO-recommended TB manage strategy known as DOTS. [Online.] http://www.who.int/tb/dots/whatisdots/en/ (4 February 2004, date last accessed)..
2. Benet, L. Z., Øie, S & Schwartz, J. (1996). Design and optimization of dosage regimens; pharmacokinetic data. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn (Hardman, J. G., Limbird, L. E., Molinoff, P. B. et al., Eds), pp. 1707–92. McGraw-Hil, New York, USA.
3. Urquhart, J. (2000). Controlled drug delivery: pharmacologic and therapeutic aspects. Journal of Internal Medicine248, 357–76.
4. Urquhart, J. (2002). History-informed perspectives on the modeling and simulation of therapeutic drug actions. In Simulation for Designing Clinical Trials (Ko, H. C. & Duffull, S., Eds), pp. 245–69. Marcel Dekker, New York, NY, USA.
5. Anonymous. (2003). Prilosec. In Physicians' Desk Reference, pp. 627–32. Medical Economics Books, Oradell, NJ, USA.